Navigation Links
New Study Shares Best Practices in Biopharma Public Relations
Date:11/6/2008

CHAPEL HILL, N.C., Nov. 6 /PRNewswire/ -- While Public Relations has long been used as a marketing tool by the pharmaceutical and biotechnology industries, its ability to reach consumers has never been greater. Web sites, online social networks, and blogs have joined the traditional press release as effective and low-cost methods that help drive sales. With this understanding, new research was conducted by Best Practices, LLC to identify what Public Relations activities are most effective at educating and informing consumers at different points in a product's lifecycle. These and other insights are now available in the newly published report, "Public Relations Excellence: Using PR to Launch, Grow and Extend Your Brands." Additional findings from this study include insights into what Public Relations channels, tactics and calls-to-action are most effective for reaching consumers of pharmaceutical products while providing three case studies highlighting successfully employed Public Relations tactics at different lifecycle stages.

To view the study abstract or complimentary summary of the full report "Public Relations Excellence: Using PR to Launch, Grow and Extend Your Brands," click on the following link http://www3.best-in-class.com/rr975.htm .

In a benchmarking study that included such influential companies as Abbott, AstraZeneca, Genentech, Johnson & Johnson, Novartis, Pfizer, and Wyeth, many key topics were covered, including:

-- PR strategies and tactics that are most effective at different

lifecycle stages

-- PR tools and calls to action that are most effective

-- Case studies that reveal effective PR practices

-- Web site resources that are most effective for consumers

-- Ideal budget ratios and performance measurements

-- Lessons learned and best practices

For more information on this report, contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr975.htm .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017  HUYA Bioscience International, (HUYA), the leader ... pharmaceutical innovations, announced today a strategic collaboration ... Investment Company (referred to as CAS Innovation). The collaboration ... by leading scientists at CAS to meet the medical ... is the first company to have recognized ...
(Date:1/18/2017)... 2017 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; ... that develops and commercializes proprietary technologies and products ... today announced that Cameron Prange , President ... from its Board of Directors.  Mr. Prange,s resignation ... that have limited both his ability to act ...
(Date:1/17/2017)... ... January 17, 2017 , ... LGC Maine Standards ... VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® SP2 evaluates Albumin, C-reactive ... SP2 kit is prepared using the CLSI recommended “equal delta” method for linearity ...
(Date:1/17/2017)... , Jan. 17, 2017 The ... at a CAGR of around 7.5% over the ... 2025. Some of the prominent trends that the ... incidences of diseases & graft transplant surgeries and ... Material the market is categorized into immunomodulatory biomaterials, ...
Breaking Biology Technology:
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
(Date:12/15/2016)... 15, 2016 Advancements in biometrics ... wellness and wellbeing (HWW), and security of ... new passenger vehicles begin to feature fingerprint ... heart beat monitoring, brain wave monitoring, stress ... and pulse detection. These will be driven ...
Breaking Biology News(10 mins):